Additional Content Download
This whitepaper, courtesy of RSM, tackles the increasingly complex pharmaceutical business model from the R&D and pre-clinical phase, through FDA approval and commercialization.
The Economic Footprint of the Pharmaceutical Industry – Regional Breakdown and Differentiation between Originators and Generics
This study independently conducted by WifOR reveals how the pharmaceutical industry, one of the world’s largest industries, plays a major role in boosting the global economy across regions. This study was commissioned by the IFPMA and aims to refine the study on ‘Measuring the economic footprint of the pharmaceutical industry – Feasibility study’ that examined for the first time the global economic importance of the pharma industry.
Social Security Finance Bill 2016 in France: French Government Looks To Make 50% Of Healthcare Savings Through Drug Price Cuts
With there being a 12.8 million Euro deficit in France’s 2015 budget, the French government announced on 24th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS; Social Security Finance Bill 2016). For the second consecutive year, the PFLSS cost-containment measures include a heavy focus on drug expenditure as part of the...
This presentation, courtesy of Deloitte, goes into types of pricing adjustments, the G2N estimation process, updates on hot G2N topics, sales returns, and more!